Phase I study with AZD2171 in patients with advanced solid malignant tumors and liver metastases
Study identifier:D8480C00001
ClinicalTrials.gov identifier:NCT00501605
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I Single centre 2-part Open study to assess the safety and tolerability of AZD2171 following single and multiple oral doses in patients with advanced solid malignant tumors and liver metastases
Medical condition
advanced solid tumor
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2171
Sex
All
Actual Enrollment
80
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 28 Feb 2003
Primary Completion Date: 30 Apr 2005
Study Completion Date: 28 Feb 2006
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Feb 2025 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Nick Botwood
AstraZeneca
